Current
33.4×
5-Year Average
68.1×
All-Time High
923.3×
All-Time Low
5.7×
P/E Ratio daily chart for Merck & Co. (MRK)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/E Ratio for Merck & Co. (MRK) from 2001 to 2025
| 2025 | $260.48B | $18.25B | 14.3× | -0.5× | |
| 2024 | $252.78B | $17.12B | 14.8× | -748.1× | |
| 2023 | $278.46B | $365.00M | 762.9× | +743.5× | |
| 2022 | $281.37B | $14.52B | 19.4× | +4.5× | |
| 2021 | $193.67B | $13.05B | 14.8× | -13.1× | |
| 2020 | $197.36B | $7.07B | 27.9× | +5.6× | |
| 2019 | $220.18B | $9.84B | 22.4× | -8.0× | |
| 2018 | $188.89B | $6.22B | 30.4× | -30.0× | |
| 2017 | $144.67B | $2.40B | 60.4× | +21.0× | |
| 2016 | $154.29B | $3.92B | 39.4× | +7.8× | |
| 2015 | $140.09B | $4.44B | 31.5× | +18.6× | |
| 2014 | $153.69B | $11.92B | 12.9× | -18.8× | |
| 2013 | $139.70B | $4.40B | 31.7× | +12.6× | |
| 2012 | $118.16B | $6.17B | 19.2× | +1.7× | |
| 2011 | $109.32B | $6.27B | 17.4× | -105.5× | |
| 2010 | $105.86B | $861.30M | 122.9× | +117.2× | |
| 2009 | $73.48B | $12.90B | 5.7× | -2.1× | |
| 2008 | $61.19B | $7.81B | 7.8× | -28.9× | |
| 2007 | $120.20B | $3.28B | 36.7× | +16.4× | |
| 2006 | $90.21B | $4.43B | 20.3× | +6.0× | |
| 2005 | $66.28B | $4.63B | 14.3× | +2.6× | |
| 2004 | $67.86B | $5.81B | 11.7× | -2.7× | |
| 2003 | $98.00B | $6.83B | 14.3× | -2.6× | |
| 2002 | $121.28B | $7.15B | 17.0× | -0.5× | |
| 2001 | $127.35B | $7.28B | 17.5× | — |
- 202514.3×
- 202414.8×
- 2023762.9×
- 202219.4×
- 202114.8×
- 202027.9×
- 201922.4×
- 201830.4×
- 201760.4×
- 201639.4×
- 201531.5×
- 201412.9×
- 201331.7×
- 201219.2×
- 201117.4×
- 2010122.9×
- 20095.7×
- 20087.8×
- 200736.7×
- 200620.3×
- 200514.3×
- 200411.7×
- 200314.3×
- 200217.0×
- 200117.5×
About P/E Ratio at Merck & Co. (MRK)
Merck & Co. (MRK) P/E ratio is 33.4× as of June 5, 2026. The 5-year average is 68.1×. The sector median currently stands at 25.0×. The current ratio is at the 76th percentile of its own 10-year history.
Merck & Co. (MRK) historical P/E ratio has ranged from a low of 5.7× (2009) to a high of 923.3× (2024) in the available daily series.
The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.
Merck & Co. P/E Ratio by Year
Merck & Co. P/E Ratio 2025: 14.3×
Merck & Co. (MRK) P/E ratio in 2025 was 14.3×, contracted from 14.8× the prior year.
Merck & Co. P/E Ratio 2024: 14.8×
Merck & Co. (MRK) P/E ratio in 2024 was 14.8×, contracted from 762.9× the prior year.
Merck & Co. P/E Ratio 2023: 762.9×
Merck & Co. (MRK) P/E ratio in 2023 was 762.9×, expanded from 19.4× the prior year.
Merck & Co. P/E Ratio 2022: 19.4×
Merck & Co. (MRK) P/E ratio in 2022 was 19.4×, expanded from 14.8× the prior year.
Merck & Co. P/E Ratio 2021: 14.8×
Merck & Co. (MRK) P/E ratio in 2021 was 14.8×.
Sector peers by P/E Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/E Ratio — table
Healthcare peers of Merck & Co. (MRK), ranked by P/E ratio.
| 22.2× | |
| 22.2× | |
| 21.7× | |
| 21.6× | |
| 21.6× | |
| 21.1× | |
| 21.1× | |
| 21.0× | |
| 20.9× | |
| 20.7× | |
| 20.4× | |
| 19.7× | |
| 18.9× | |
| 18.8× | |
| 18.5× | |
| 18.2× | |
| 17.0× | |
| 15.8× | |
| 13.3× | |
| 13.1× | |
| 12.3× | |
| 11.1× | |
| 8.6× | |
| 7.9× | |
| 7.2× |
- 22.2×
- 22.2×
- 21.7×
- 21.6×
- 21.6×
- 21.1×
- 21.0×
- 20.9×
- 20.7×
- 19.7×
- 18.9×
- 18.5×
- 15.8×
- 13.3×
- 13.1×
- 11.1×
- 7.9×
Frequently asked questions
Merck & Co. (MRK) Key Financials
Charts, filings, and peer comparison for every metric